2020
Exenatide extended release in patients with type 1 diabetes with and without residual insulin production
Herold KC, Reynolds J, Dziura J, Baidal D, Gaglia J, Gitelman SE, Gottlieb PA, Marks J, Philipson LH, Pop‐Busui R, Weinstock RS. Exenatide extended release in patients with type 1 diabetes with and without residual insulin production. Diabetes Obesity And Metabolism 2020, 22: 2045-2054. PMID: 32573927, PMCID: PMC8009602, DOI: 10.1111/dom.14121.Peer-Reviewed Original ResearchMeSH KeywordsDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2ExenatideGlycated HemoglobinHumansHypoglycemic AgentsInsulinVenomsConceptsExenatide extended releaseResidual insulin productionBeta-cell functionType 1 diabetesC-peptidePlacebo groupPrimary outcomeWeek 12ER groupInsulin productionDetectable C-peptide levelsResidual beta-cell functionGLP-1 receptor agonistsRandomized placebo-controlled trialExtended releaseTotal insulin doseMean HbA1c levelPlacebo-controlled trialC-peptide levelsDetectable levelsCell functionShort-term improvementHbA1c levelsStudy drugAdverse events
2018
Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis
Perdigoto AL, Preston-Hurlburt P, Clark P, Long SA, Linsley PS, Harris KM, Gitelman SE, Greenbaum CJ, Gottlieb PA, Hagopian W, Woodwyk A, Dziura J, Herold KC. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis. Diabetologia 2018, 62: 655-664. PMID: 30569273, PMCID: PMC6402971, DOI: 10.1007/s00125-018-4786-9.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntibodies, Monoclonal, HumanizedArea Under CurveAutoimmunityCD3 ComplexCD8-Positive T-LymphocytesChildC-PeptideCytokinesDiabetes Mellitus, Type 1FemaleFollow-Up StudiesHumansHypoglycemic AgentsInsulinIslets of LangerhansMaleRandomized Controlled Trials as TopicRemission InductionTreatment OutcomeYoung AdultConceptsC-peptide responseType 1 diabetesMixed meal tolerance testDetectable C-peptideC-peptideInsulin useTolerance testT cellsControl groupNew-onset type 1 diabetesPeripheral blood mononuclear cellsConclusions/interpretationThese findingsAnti-CD3 monoclonal antibodyDaily insulin useBlood mononuclear cellsDiagnosis of diabetesSuccessful immune therapiesOriginal control groupCell death proteinAnergic CD8ResultsFifty-sixImmune therapyInterpretationThese findingsMononuclear cellsCytokine release
2012
Effects on post-prandial glucose and AGE precursors from two initial insulin strategies in patients with Type 2 diabetes uncontrolled by oral agents
Sakharova OV, Lleva RR, Dziura JD, Spollett GR, Howell SK, Beisswenger PJ, Inzucchi SE. Effects on post-prandial glucose and AGE precursors from two initial insulin strategies in patients with Type 2 diabetes uncontrolled by oral agents. Journal Of Diabetes And Its Complications 2012, 26: 333-338. PMID: 22541894, DOI: 10.1016/j.jdiacomp.2012.03.027.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAgedBlood GlucoseBody WeightCross-Over StudiesDiabetes Mellitus, Type 2FastingFemaleGlycated HemoglobinGlycation End Products, AdvancedHumansHypoglycemic AgentsInsulin GlargineInsulin LisproInsulin, Long-ActingMaleMiddle AgedPostprandial PeriodTreatment FailureTreatment OutcomeConceptsOral anti-hyperglycemic drugsPost-prandial glucoseInsulin strategiesFree fatty acidsType 2Post-prandial glucose metabolismProgressive β-cell dysfunctionType 2 diabetes patientsPost-prandial glucose levelsDaily insulin glargineInitial insulin regimenPrecursor of AGEsSingle-center studyClinical Research CenterLong-term diabetic complicationsAnti-hyperglycemic drugsType 2 diabetesΒ-cell dysfunctionCross-over designInitial insulinInsulin regimenOral agentsInsulin regimensInsulin therapyOAD therapy
2010
Early Pharmacokinetic and Pharmacodynamic Effects of Mixing Lispro With Glargine Insulin Results of glucose clamp studies in youth with type 1 diabetes
Cengiz E, Tamborlane WV, Martin-Fredericksen M, Dziura J, Weinzimer SA. Early Pharmacokinetic and Pharmacodynamic Effects of Mixing Lispro With Glargine Insulin Results of glucose clamp studies in youth with type 1 diabetes. Diabetes Care 2010, 33: 1009-1012. PMID: 20150302, PMCID: PMC2858163, DOI: 10.2337/dc09-2118.Peer-Reviewed Original ResearchConceptsType 1 diabetesGlucose clamp studiesGlucose excursionsClamp studiesMeal-related glucose excursionsRapid-acting insulin analoguesRapid-acting insulinEuglycemic glucose clampTime-action curvePharmacodynamic peakA1c levelsTreatment burdenPharmacodynamic effectsDaily injectionsUnits/Pharmacodynamic actionClinical studiesGlucose clampMixed injectionGlargineEarly pharmacokineticsInsulin analoguesObjective clinicianInsulin pharmacokineticsLispro
2008
Effect of Age of Infusion Site and Type of Rapid-Acting Analog on Pharmacodynamic Parameters of Insulin Boluses in Youth With Type 1 Diabetes Receiving Insulin Pump Therapy
Swan KL, Dziura JD, Steil GM, Voskanyan GR, Sikes KA, Steffen AT, Martin ML, Tamborlane WV, Weinzimer SA. Effect of Age of Infusion Site and Type of Rapid-Acting Analog on Pharmacodynamic Parameters of Insulin Boluses in Youth With Type 1 Diabetes Receiving Insulin Pump Therapy. Diabetes Care 2008, 32: 240-244. PMID: 19017777, PMCID: PMC2628686, DOI: 10.2337/dc08-0595.Peer-Reviewed Original ResearchConceptsInsulin pump therapyGlucose infusion rateType 1 diabetesDay 1Day 4Pump therapyInsulin aspartPharmacodynamic parametersInsulin actionInsulin bolusRapid acting analogsEuglycemic clamp procedureExogenous glucose infusionGIR curveEffect of agePharmacodynamic measuresPharmacodynamic characteristicsClamp procedureInfusion siteGlucose infusionInfusion rateInsulin analoguesType 1AspartOverall insulin actionShort‐term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance
Burgert TS, Duran EJ, Goldberg‐Gell R, Dziura J, Yeckel CW, Katz S, Tamborlane WV, Caprio S. Short‐term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance. Pediatric Diabetes 2008, 9: 567-576. PMID: 18761646, DOI: 10.1111/j.1399-5448.2008.00434.x.Peer-Reviewed Original ResearchConceptsNormal glucose toleranceInsulin sensitivityGlucose toleranceObese childrenDouble-blind clinical trialType 2 diabetes mellitusSubcutaneous fatCardio-metabolic consequencesBaseline insulin sensitivityImproved insulin sensitivityInsulin-resistant adolescentsHeart rate recoveryLong-term treatmentDeep subcutaneous fatShort-term useMagnetic resonance imagingPlacebo groupCardiovascular effectsDiabetes mellitusMetS groupClinical effectsLipid parametersInsulin sensitizersInflammatory cytokinesObese adolescents
2006
Optimal control of type 1 diabetes mellitus in youth receiving intensive treatment
Springer D, Dziura J, Tamborlane WV, Steffen AT, Ahern JH, Vincent M, Weinzimer SA. Optimal control of type 1 diabetes mellitus in youth receiving intensive treatment. The Journal Of Pediatrics 2006, 149: 227-232. PMID: 16887440, DOI: 10.1016/j.jpeds.2006.03.052.Peer-Reviewed Original ResearchConceptsType 1 diabetes mellitusRace/ethnicityLow socioeconomic statusSocioeconomic statusDiabetes mellitusLarge clinical practiceDuration of diabetesOptimal glycemic controlBody mass indexPoor metabolic controlAge 18 yearsGlycemic targetsInjection therapyGlycemic controlDiabetes controlMass indexFemale sexDatabase reviewInsulin administrationIntensive treatmentMonths durationTrial recommendationsMultiple linear regression analysisTherapeutic goalsClinical practice